Related references
Note: Only part of the references are listed.High fracture probability with FRAX((R)) usually indicates densitometric osteoporosis: implications for clinical practice
W. D. Leslie et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Screening for Osteoporosis: US Preventive Services Task Force Recommendation Statement
Ned Calonge et al.
ANNALS OF INTERNAL MEDICINE (2011)
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
P. Hadji et al.
ANNALS OF ONCOLOGY (2011)
Identifying Factors Associated With Falls in Postmenopausal Breast Cancer Survivors: A Multi-Disciplinary Approach
Kerri M. Winters-Stone et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2011)
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study
Daniel Prieto-Alhambra et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial
Antonella L. Rastelli et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
Susan F. Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial
Kerri M. Winters-Stone et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Breast cancer and bone mineral density: The Marburg Breast Cancer and Osteoporosis Trial (MABOT II)
M. Kalder et al.
CLIMACTERIC (2011)
Changes in Weight and Body Composition in Women Receiving Chemotherapy for Breast Cancer
Mary Jo Nissen et al.
CLINICAL BREAST CANCER (2011)
Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer
Beatrice J. Edwards et al.
CLINICAL CANCER RESEARCH (2011)
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies
Peyman Hadji et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Effect of Endocrine Therapies on Bone in Breast Cancer Patients
R. J. Santen
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Summary of the Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older Persons
Rose Anne M. Kenny et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2011)
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Paul E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mortality rates after incident non-traumatic fractures in older men and women
S. Morin et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Pharmacology of arthralgia with estrogen deprivation
Anneleen Lintermans et al.
STEROIDS (2011)
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
Stephanie Gaillard et al.
BREAST CANCER RESEARCH (2011)
Immunological Therapies Can Relieve Aromatase Inhibitor-Related Joint Symptoms in Breast Cancer Survivors
Qingyuan Zhang et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
The use of Nolvadex in the treatment of generic Tamoxifen-associated small joint arthralgia
N. S. Blencowe et al.
BREAST (2010)
New views on treatment of aromatase inhibitors induced arthralgia
Gr. Xepapadakis et al.
BREAST (2010)
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer
Qamar J. Khan et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?
David A. Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Omar S. Din et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis
Myrthe P. P. van Herk-Sukel et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Assessment of fracture risk in women with breast cancer using current vs emerging guidelines
P. Hadji et al.
BRITISH JOURNAL OF CANCER (2010)
Rheumatic Disorders and Functional Disability With Aromatase Inhibitor Therapy
George Moxley
CLINICAL BREAST CANCER (2010)
Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey
S. Saibil et al.
Current Oncology (2010)
Managing the toxicities of the aromatase inhibitors
Joanne E. Mortimer
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2010)
Effect of menopause on femoral and vertebral bone loss
J.M. Pouilles et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of a one-year high-intensity versus low-intensity resistance training program on bone mineral density in older women
Leslie A. Pruitt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Fracture Risk Prediction Using BMD and Clinical Risk Factors in Early Postmenopausal Women: Sensitivity of the WHO FRAX Tool
Florence A. Tremollieres et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Randomized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor-Associated Joint Symptoms in Women With Early-Stage Breast Cancer
Katherine D. Crew et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
James N. Ingle et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Managing Aromatase Inhibitors in Breast Cancer Survivors: Not Just for Oncologists
Julia A. Files et al.
MAYO CLINIC PROCEEDINGS (2010)
American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors
Kathryn H. Schmitz et al.
MEDICINE & SCIENCE IN SPORTS & EXERCISE (2010)
Management of osteoporosis in postmenopausal women
&NA;
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2010)
The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial
N. L. Waltman et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Primary Care Use of FRAX (R): Absolute Fracture Risk Assessment in Postmenopausal Women and Older Men
Ethel S. Siris et al.
POSTGRADUATE MEDICINE (2010)
A review of exercise interventions to improve bone health in adult cancer survivors
Kerri M. Winters-Stone et al.
JOURNAL OF CANCER SURVIVORSHIP (2010)
Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
Qamar J. Khan et al.
JOURNAL OF ONCOLOGY (2010)
A meta-analysis of impact exercise on postmenopausal bone loss: the case for mixed loading exercise programmes
M. Martyn-St James et al.
BRITISH JOURNAL OF SPORTS MEDICINE (2009)
The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer
Peyman Hadji et al.
EUROPEAN JOURNAL OF CANCER (2009)
NCCN Task Force Report: Bone Health in Cancer Care
Julie R. Gralow et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
A Randomized Trial to Increase Physical Activity in Breast Cancer Survivors
Laura Q. Rogers et al.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2009)
Progression Models in Resistance Training for Healthy Adults
Nicolas A. Ratamess et al.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2009)
PERIPHERAL ESTRADIOL INDUCES TEMPOROMANDIBULAR JOINT ANTINOCICEPTION IN RATS BY ACTIVATING THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE SIGNALING PATHWAY
N. C. Favaro-Moreira et al.
NEUROSCIENCE (2009)
Exercise Improves Body Fat, Lean Mass, and Bone Mass in Breast Cancer Survivors
Melinda L. Irwin et al.
OBESITY (2009)
Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative
Z. Chen et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Excess mortality following hip fracture: a systematic epidemiological review
B. Abrahamsen et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Bone Health and Falls: Fracture Risk in Breast Cancer Survivors With Chemotherapy-Induced Amenorrhea
Kerri M. Winters-Stone et al.
ONCOLOGY NURSING FORUM (2009)
Meta-analysis of walking for preservation of bone mineral density in postmenopausal women
Marrissa Martyn-St James et al.
BONE (2008)
Effectively nursing patients receiving aromatase inhibitor therapy
Y. Wengstrom
BREAST (2008)
Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations
R. E. Coleman et al.
CANCER TREATMENT REVIEWS (2008)
Bone boss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies
Robert E. Coleman et al.
CANCER TREATMENT REVIEWS (2008)
Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference
Sanford Baim et al.
JOURNAL OF CLINICAL DENSITOMETRY (2008)
Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer
Fred Saad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Biomarkers for osteoporosis management - Utility in diagnosis, fracture risk prediction and therapy monitoring
Patrick Garnero
MOLECULAR DIAGNOSIS & THERAPY (2008)
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis
Ivana Sestak et al.
LANCET ONCOLOGY (2008)
Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy
Judith K. Payne et al.
ONCOLOGY NURSING FORUM (2008)
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy
David Cella et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
Raimund Jakesz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging
Leilani Morales et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Exercise Effects on Bone Mineral Density in Women With Breast Cancer Receiving Adjuvant Chemotherapy
Anna L. Schwartz et al.
ONCOLOGY NURSING FORUM (2007)
Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial
Jack Cuzick et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Twenty-year follow-up of the royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
Trevor J. Powles et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
Robert E. Coleman et al.
LANCET ONCOLOGY (2007)
Site-specific response of bone to exercise in premenopausal women
Kerri M. Winters-Stone et al.
BONE (2006)
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
Stephen E. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Health behaviors in breast cancer survivors experiencing bone loss
Janice J. Twiss et al.
JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS (2006)
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women
Henning T. Mouridsen
CURRENT MEDICAL RESEARCH AND OPINION (2006)
High-intensity resistance training and postmenopausal bone loss: a meta-analysis
M. Martyn-St James et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
G. Francini et al.
BRITISH JOURNAL OF CANCER (2006)
Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status
L Vehmanen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
F. Boccardo et al.
ANNALS OF ONCOLOGY (2006)
Progressive high-intensity resistance training and bone mineral density changes among premenopausal women - Evidence of discordant site-specific skeletal effects
Marrissa Martyn-St James et al.
SPORTS MEDICINE (2006)
Immune responses and bone loss: the estrogen connection
H Carlsten
IMMUNOLOGICAL REVIEWS (2005)
Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer - Results from a subgroup in the women's health initiative. Observational study
Z Chen et al.
CANCER (2005)
Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer
LM Rodríguez-Rodríguez et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
R Jakesz et al.
LANCET (2005)
Fracture risk among breast cancer survivors - Results from the Women's Health Initiative Observational Study
Z Chen et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy
A Sverrisdóttir et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bone mineral density and adjuvant therapy in breast cancer survivors
C Crandall et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands)
J Sautner et al.
RHEUMATOLOGY (2004)
Physical activity and bone health
WM Kohrt et al.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2004)
Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis - The arthritis, diet, and activity promotion trial
SP Messier et al.
ARTHRITIS AND RHEUMATISM (2004)
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
I Fogelman et al.
OSTEOPOROSIS INTERNATIONAL (2003)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The prevalence of symptoms possibly related to the climacteric in pre- and postmenopausal women in Linkoping, Sweden
C Jansson et al.
MATURITAS (2003)
The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer
NC Greep et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Physical activity levels before and after a diagnosis of breast carcinoma - The health, eating, activity, and lifestyle (HEAL) study
ML Irwin et al.
CANCER (2003)
American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
BE Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Diagnosis of osteoporosis and assessment of fracture risk
JA Kanis
LANCET (2002)
Bone strength at clinically relevant sites displays substantial heterogeneity and is best predicted from site-specific bone densitometry
F Eckstein et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients.: The effect of adjuvant clodronate treatment
L Vehmanen et al.
EUROPEAN JOURNAL OF CANCER (2001)
Should future risk-of-fracture analyses include another major risk factor? The case for falls
HM Frost
JOURNAL OF CLINICAL DENSITOMETRY (2001)
Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer
CL Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer
T Saarto et al.
BRITISH JOURNAL OF CANCER (2001)
Quantitative ultrasound: An indicator of osteoporosis in perimenopausal women
J Nairus et al.
JOURNAL OF CLINICAL DENSITOMETRY (2000)
Femoral bone mineral density, neck-shaft angle and mean femoral neck width as predictors of hip fracture in men and women
CG Alonso et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
